$DHT-UN.TO

DRI Healthcare Trust Price Target Raised to $23.00 at Stifel Canada

Stifel Canada raised its price target on the units of DRI Healthcare Trust (DHT-UN.TO) by $1.00 to $23.00 and maintained its buy rating.Analyst Justin Keywood noted DRI reported "very strong" first-quarter results: total income of US$50.6 million was a 14% beat versus Stifel Canada's US$44.4 million estimate, and represented overall growth of 15% y/y."We highlight adj. EBITDA margins on Total Income (104.3%) and on Cash Receipts (90.4%) as highly impressive and reflect the structurally higher margin profile of the business following the manager internalization last year."Keywood also flagged Orserdu, an oral hormonal therapy, and a core royalty interest for DRI that faces near-term competitive pressure, becoming more pronounced through 2026/early 2027. Keywood believes DRI's next transaction will serve as a meaningful catalyst to allay investor concerns around the uncertainty in Orserdu's decline.Price: $16.26, Change: $+0.12, Percent Change: +0.74%

Earnings Flash (DHT-UN.TO) DRI Healthcare Trust Reports Q1 Total Income $50.6M

DRI Healthcare Trust Says Looking at Implications For It From the Proposed Acquisition Of KalVista

DRI Healthcare Trust (DHT-UN.TO) after trade Wednesday noted the announcement by KalVista Therapeutics that it entered into a definitive agreement to be acquired by Chiesi Group, an international research-focused biopharmaceutical group, and said it is looking at the implications for the deal for itself.DRI Healthcare is entitled to worldwide net sales of all formulations of Ekterly (sebetralstat) under a royalty agreement with KalVista. Based on publicly available information, the KalVista transaction, if consummated, may constitute a change of control under DRI Healthcare's royalty agreement, it said.It added: "DRI Healthcare is currently reviewing the announced transaction and evaluating its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the transaction. No determination has been made at this time with respect to any actions DRI Healthcare may take in connection with the transaction."DRI units closed up $0.04 to $16.45 on the Toronto Stock Exchange.